医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Herbalife Honored with Consumer Protection Guarantee Award in Thailand

2013年05月04日 AM05:40
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Herbalife (NYSE: HLF) has been presented with a Consumer Protection Guarantee award in Thailand. The award is given by the Consumer Protection Board (OCPB), which operates under the supervision of the Office of the Prime Minister of Thailand.

Presented by the Prime Minister’s Office as part of the Thai Consumer Protection Day event, the award recognizes Herbalife’s commitment to consumer protection and its dedication to providing high quality nutrition products to Thai consumers.

The Consumer Protection Guarantee award also highlights Herbalife’s adherence to Thailand’s consumer’s protection law, and serves as testament to the company’s financial strength and operational transparency, both key indicators for the OCPB.

The Consumer Protection Guarantee program was initiated by the OCPB in 2012 with the ultimate goal of engendering consumer confidence in businesses across 26 major sectors in preparation for Thailand’s integration into the ASEAN Economic Community.

About Herbalife Ltd.

Herbalife Ltd. (NYSE:HLF) is a global nutrition company that sells weight-management, nutrition and personal care products intended to support a healthy lifestyle. Herbalife products are sold in more than 80 countries to and through a network of independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to help bring good nutrition to children. Herbalife’s website contains information about Herbalife, including financial and other information at www.herbalife.com.

CONTACT

Herbalife
Julian Cacchioli
213-745-0519
julianc@herbalife.com
or
Khun
Wandee Lerdsupongkit
+66 02 233 4329
pr@francomasia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表